Assessment of the impact of reconstitution therapies—cladribine tablets and alemtuzumab—on the atrophy progression among patients with relapse-remitting multiple sclerosis

Assessment of the impact of reconstitution therapies—cladribine tablets and alemtuzumab—on the atrophy progression among patients with relapse-remitting multiple sclerosis

IntroductionImmune reconstitution therapies (IRT) are highly effective therapies for multiple sclerosis (MS). Among IRT, we can distinguish partially selective therapies such as cladribine in tablets (CLAD) and non-selective therapies, which include alemtuzumab (ALEM). Today, it is known that these...

Full description

Saved in:
Bibliographic Details
Main Authors: Aleksandra Pogoda-Wesołowska, Ignacy Stachura, Arkadiusz Zegadło, Marzena Maciągowska-Terela, Karolina Sobolewska, Aleksander Dębiec, Jacek Staszewski, Adam Stępień
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Neuroscience
Subjects:
reconstitution therapies
multiple sclerosis
atrophy
volumetric changes
cladribine tablets
alemtuzumab
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2025.1531163/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2025.1531163/full

Similar Items